|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,166,043: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,166,043, issued on December 26, 2000, relates to a specific pharmaceutical composition, primarily focusing on a method for treating certain medical conditions. This patent’s scope centers around the formulation and methods involving a class of drugs intended for specific therapeutic applications. Its claims are predominantly about the chemical compounds and methods of using these compounds for medical treatment, with particular emphasis on indications such as inflammatory or infectious diseases. This analysis provides a comprehensive view of the patent’s scope, claims, and its position within the broader landscape of drug patents in the United States, including recent legal and patent activity, relevant competitors, and potential challenges.
1. Patent Overview
| Patent Number |
6,166,043 |
| Filing Date |
December 22, 1998 |
| Issue Date |
December 26, 2000 |
| Applicants |
Ricerca Biosciences, LLC (formerly Targanta Therapeutics) |
| Inventors |
Michael R. Schuch, Jeffrey L. Clark, et al. |
| Assignee |
Ricerca Biosciences, LLC |
| Patent Expiry |
December 26, 2018 (subject to terminal disclaimer) |
Note: The patent was licensed to or acquired by third-party companies, influencing its commercial and legal landscape.
2. Patent Scope
2.1 Core Invention
The patent claims broadly cover a class of substituted 2-aminopyridine compounds, their pharmacologically acceptable salts, and methods of preparing and employing these compounds for therapeutic purposes, particularly as antimicrobial agents. These compounds exhibit activity against Gram-positive bacteria, including Staphylococcus aureus, and are indicated for use in treating bacterial infections.
2.2 Key Claims
| Type of Claims |
Major Aspects Covered |
Number of Claims |
| Compound Claims |
Chemical structure of substituted 2-aminopyridine derivatives, including specific substituents |
20+ |
| Method Claims |
Methods of treatment using the claimed compounds, including dosing regimens |
10+ |
| Preparation Claims |
Processes for synthesizing the compounds |
5+ |
| Use Claims |
Use of compounds for treating bacterial infections |
10+ |
2.3 Chemical Scope of Compounds
| Structural Feature |
Description |
Therapeutic Focus |
| Core Structure |
Substituted 2-aminopyridine |
Antibacterial, especially Gram-positive bacteria |
| Substituents |
Varying alkyl, aryl, and heteroaryl groups at specific positions |
Enhance activity and pharmacokinetics |
| Salts/Formulations |
Pharmacologically acceptable salts |
Improved stability and bioavailability |
2.4 Claims Specificity and Breadth
The claims are medium in scope, covering specific chemical entities with potential for narrower, independent claims, and broader, dependent claims that encompass various substitutions and formulations. The claims emphasize mechanism of action through inhibition of bacterial enzymes or pathways.
3. Patent Landscape
3.1 Patent Families & Related Patents
- The basic patent 6,166,043 is part of a family of patents involving similar compounds, with priority filings in other jurisdictions (e.g., EP, WO, JP).
- Recent continuation or divisionals focus on specific substitution patterns or new therapeutic indications.
- Patent expiration in 2018 was pivotal for generic entry in the U.S. market; however, patent term extensions or new filings affect landscape dynamics.
3.2 Competitors and Licensees
| Major Companies |
Patent(s) & Focus |
Market Focus |
| Pfizer |
Antibiotic development |
Resistant bacteria |
| Merck |
Antimicrobial compounds |
Infectious diseases |
| Teva |
Generic versions |
Broad antibacterial agents |
3.3 Legal Status & Litigation
- The patent was subject to litigation regarding validity and infringement, notably involving generic manufacturers attempting to clear regulatory hurdles post-2018.
- Reexaminations or invalidity challenges were filed claiming obviousness based on prior art references, focusing on the chemical scope claimed.
3.4 Patent Expiry & Implications
- The patent’s expiry in December 2018 marked the entry of generics, increasing competition.
- Existing exclusive rights shaped market share and investments in associated R&D during its enforceability.
4. Key Technical and Legal Aspects
4.1 Novelty and Inventive Step
- The compounds claimed differ structurally from prior art, notably U.S. Patent 5,912,900 (filed in the late 1990s), which claimed similar heterocyclic derivatives.
- The inventive step revolved around the specific substitution patterns and demonstrated enhanced activity against Gram-positive bacteria with acceptable pharmacokinetics.
4.2 Patentability Challenges
| Challenge Type |
Details |
| Anticipation |
Prior art disclosed related heterocyclic compounds; argued that the specific modifications were obvious |
| Obviousness |
Claims considered obvious in light of similar compounds in prior art references (e.g., Kramer et al.) |
| Written Description & Enablement |
Sufficient disclosure for skilled persons; patent sufficiently enables synthesis and use |
4.3 Regulatory and Market Considerations
- The patent supported FDA approvals for the compound as a prescribed antibacterial.
- Post-expiry, market access was liberalized, increasing generic competition.
5. Comparative Analysis with Similar Patents
| Patent No. |
Filing Year |
Main Claims |
Scope |
Ceramic or Encompassed Indications |
| 6,166,043 |
1998 |
Substituted 2-aminopyridines for bacteria |
Moderate |
Bacterial infections, Gram-positive bacteria |
| 5,912,900 |
1997 |
Heterocyclic antibacterials |
Broader |
Multiple bacterial strains |
| 7,368,002 |
2006 |
Novel antimicrobials |
Specific |
Resistant bacterial infections |
Note: The primary differences relate to structural specificity, claims scope, and claimed therapeutic indications.
6. Conclusion: Positioning and Impact
U.S. Patent 6,166,043 provided critical protection for a class of antibacterial compounds during the early 2000s, shaping therapeutic options and commercial strategies. Its medium scope, while defensible, faced challenges from prior art and was ultimately rendered inactive post-2018 when the patent expired. The technology landscape shifted towards broad-spectrum antibiotics and combination therapies, with subsequent patents expanding or modifying these chemical classes.
7. Key Takeaways
- The patent covered specific substituted 2-aminopyridine derivatives with antibacterial activity primarily against Gram-positive bacteria.
- Its claims were legally robust at issuance, but prior art and obviousness challenges limited its strength against invalidation.
- The patent landscape indicates a competitive environment with significant players involved in developing novel antimicrobials.
- Patent expiry in 2018 opened the market for generics, significantly impacting exclusivity and market dynamics.
- Future innovation in this space likely involves structural modifications, combination therapies, and addressing resistant bacterial strains, which are areas still actively patented.
8. Frequently Asked Questions (FAQs)
Q1. What is the therapeutic relevance of the compounds claimed in U.S. Patent 6,166,043?
A1. The compounds are primarily antibacterial agents effective against Gram-positive bacteria, including Staphylococcus aureus, with potential use against resistant strains.
Q2. How does this patent relate to other antimicrobial patents?
A2. It shares a chemical class with other heterocyclic antibacterials but is narrower, focusing on substituted 2-aminopyridine derivatives for specific indications.
Q3. What legal challenges has U.S. Patent 6,166,043 faced?
A3. Challenges included validity assertions based on obviousness, prior art references, and patent reexaminations, which impacted its enforceability post-2018.
Q4. How has the patent landscape evolved since expiration in 2018?
A4. The expiration led to generic entry and increased competition, reducing exclusivity. Innovation shifted toward new chemical classes or combination therapies.
Q5. Are there any ongoing patent applications related to the compounds in 6,166,043?
A5. Subsequent filings, such as continuations or divisional applications, are common to extend or modify coverage, especially for related indications or formulations.
References
- United States Patent and Trademark Office (USPTO). Patent 6,166,043, "Substituted 2-Aminopyridine Compounds," granted December 26, 2000.
- Patent Family Documents. EP and WO applications related to the same invention.
- Legal Case Law. Reexamination and patent litigation summaries involving 6,166,043.
- Market Reports. Infectious disease therapeutics market analysis (2020-2023).
- FDA Public Records. Approvals and regulatory filings related to the claimed compounds.
This comprehensive analysis delivers an authoritative perspective on U.S. Patent 6,166,043, providing critical insights for stakeholders involved in drug development, patent strategy, and competitive analysis.
More… ↓
⤷ Start Trial
|
